Clinical Trial Update: An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

View source ↗

Summary

An observational, prospective, multicenter study evaluating the use and outcomes of biologic therapies in Chinese asthma patients, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Biologic therapies for asthma (unspecified)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Status: ACTIVE_NOT_RECRUITING